СПИСОК ЛИТЕРАТУРЫ

1. Абдул Кадыров К.М., Грицаев С.В., Рукавицын О. А. и др. Применение иммуносупрессивной терапии для лечения больных первичным миелодиспластическим синдромом. Украинский журнал гематологии и граисфузиологии - №3 (1) - 2001, стр.

2. Брандализа С., Лопес Л. Клинические особенности миелодиспластического синдрома у детей в Бразилии. Гематология и трансфузиология, 1995, №2, стр. 18-19.

3. Владимирская Е.Б., Масчан А.А., Румянцев А.Г. Апоптоз и его роль в развитии опухолевого роста. Гемат. и трансфуз., 1997, том 42, №5, стр. 4-9.

4. Георгии А., Бюр Т., Машек X. и др. Гистопатология

миелодиспластического синдрома: вопросы диагностики,

гипопластический вариант и проблемы вторичного МДС. Гематология и трансфузиология, 1995, №2, стр. 11.

5. Гладыш В.В. Клиника и диагностика идиопатических миелодиспластичсских синдромов (рефрактерных анемий): Автореф. дис.... канд. мед. наук.М., 1998.

6. Гоасген Ж. Прогностические факторы при миелодиспластическнх синдромах: специфические аспекты у детей. Гематология и трансфузиология, 1995, №2, стр. 10.

7. Зумбос Н. К. вопросу о взаимоотношении апластической анемии и миелодиспластического синдрома. Гемат. и трансфуз., 1999, №4, стр.23-

25.

8. Михайлова Е.А. Программное лечение взрослых больных

апластической анемией, док. диссертация, Москва, 2001 год.

9. Никитин Д., Торубарова Н., Маякова С. Результаты изучения миелодиспластического синдрома у детей Москвы и Санкт-Петербурга. Гематология и трансфузиология, 1995, №2, стр. 19-20.

Увеличение процента бластных клеток в периферической крови и костном мозге, появление новых хромосомных аномалий, свидетельствует о прогрессии заболевания и требует рассмотрение вопроса о смене терапии и назначения цитостатичесой терапии.

Новиков В.С. Программированная клеточная гибель. Санкт-Петербург, 1996.

Кохно А.В. Терапия рефрактерных анемий и острых малопроцентных лейкозов.

Савченко В.Г., Паровичникова Е.Н., Михайлова Е.А. и др. Миелодиспластический синдром: некоторые вопросы патогенеза и лечения. Терапевтический архив, 1996, том 68, №7, стр. 34-37.

Турбина Н.С. Депрессии кроветворения. Под ред. О.К. Гаврилова, Ф.Э. Файнштейна, Н.С. Турбиной. - М., 1987. - стр. 138 - 152.

Тчерния Г., Миелот Ф., Бадер - Менье Б. и др. Рефрактерная анемия и митохондриальная цитопатия у детей. Гематология и трансфузиология, 1995, №2, стр. 16 17.

Тчерния Г. Мислодисплазия у детей: опыт французских исследователей. Гематология и трансфузиология, 1995, № 2, стр. 19.

Уманский С.Р. Апоптоз: молекулярные и клеточные механизмы. Молекулярная биология, 1996,Том 30, вып. 3, стр.487-497.

Хасле X., Керндруп Г. Эпидемиология миелодиспластического синдрома у детей. Гематология и трансфузиология, 1995, №2, стр. 8. Ширин А.Д., Волкова М.А., Френкель М.А. Миелодиспластические синдромы. Клиническая онкогематология. Москва 2001 г., стр. 214 - 236.

Яворковский Л.И., Ряузова Л.Ю., Соловей Д.Я., Яворковский Л.Л. Миелодиспластический синдром. Первичная миелопоэтическая дисплазия. Рига 1992 г.

Aguayo A., Kantarjiau Н., Manshouri Т. et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood, 2000,Vol.96, № 6, P.2240-2245.

Ahlo H. FoxPro 2: A Developer’s Guide. - 1992.

Biesma D.H., van den Twell G., Verdonck L.F. Immunosupressive therapy for hypoplastic myelodysplastic syndrome. Cancer 1997; 79; 1548 - 1551. Boultwood J., Louis S., Wainscoat J. S. The 5-q syndrome. Blood. 1994. P. 84 Bouscary D., De Vos J., Guesnu M. Fsa/Apo-1(CD95) expression and apoptosis in patients with myeiodysplastic syndromes. Leukemia, 1997,№11, P.839-845.

Bouscary D., Chen Y., Guesnu M. et al. Activity of the caspase-3/CPP32 enzyme in increase in "early stage" myeiodysplastic syndromes with excessive apoptosis, but caspase inhibition does not enhance colony formation in vitro. Exp. Haemat., 2000, Vol.28, №7, P.784-791.

Bowen D. T., Denzingcr C., Brugger W. et al. Poor response rate to a combtinuous schedule of amifostine therapy for low/intermediaterisk myeiodysplastic patients. Br. J. Haemat., 1998, Vol.103, P.785-787.

Campos L, Rouault J-Р., Sabido 0. et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood,1993, Vol. 81, P. 3091-3096.

Catalano L., Selleri C., Califano C. et al. Prolonged response to cyclosporine A in hypoplastic refractory anemia and correlation with in vitro studies. Haematologica, 2000, Vol. 85, P. 113-138.

Centenara E., Guamone R, Ippde G. et al. Cyclosporin - A in severe refractory anemia of myelofibrosis with myeloid metaplasia: a preliminary report, Haematologica 1998; 83; 622 -626.

Clark D. M., Lampert I. A. Apoptosis is a common histopathological finding in myelodysplasia: the correlate of ineffective hematopoiesis. Leuk Lymphoma, 1990, №2, P.415-418.

Cutolo M., Barone A., Accardo S. et al. Effect of cycIosporineA on apoptosis in human cultured monocytic THP-1 cells and synovial macrophages. Clin. Exp. Rheumatol. 1998,Vol. 16, №4, P.417-422.

22. Andjelic S., Khanna A., Suthanihiran M.et al. Intracellular Ca2+ elevation and cyclosporin a synergistically induce TGF-beta 1-mediated apoptosis in lymphocytes. J.lmmunol., 1997,Vol.l58, №6, P.2527-2534.

23. Anzai T., Hirose W., Nakane H et al. Myelodysplastic syndrome assoiated with immunoblastic lymphadenopathy-likc T-ccll lymphoma: simultaneous clinical improvement with chemotherapy. Jpn. J. Oncol. 1994, Vol.24, №2, P.106-110.

24. Appelbaum S._} Anderson M. And J. allogenic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score. Leukemia, 1998, Vol.12, suppl.l, P.25-29.

25. Aul C., Gattermann N., Germing U. et al. Dtsch. Med. Wchschr.-Bd.l 17.-S. 1223-1231.

26. Aul C., Germing U. Gattermann N. Leuc. Res., 1997. Vol. 21 (suppl. I). P.

S3.

27. Barll R., Frisch B., Baumgart R.

28. Barret A., Molldrem J., Saunthrajarian Y. et al. Prolonged transfusion independence and disease stability in patients with myeiodysplastic syndromes responding to antithymocyte globulin. Blood,1998, Vol.92, №10, Suppl.l, abst.2932.

29. Bauduer F., Ducout L., Capdupuy C. et al. Lcuk. Res.-1997.-Vol. 21.(suppl. 1).-P. 5.

30. Bennett J., Catovsky D., Daniel M. et al. Proposals for the classification of the myeiodysplastic syndromes. Br.J.Haematol.,1982,Vol.51, №2, P. 189-199.

31. Beran M., Estey E., O’Brien S. et al. Topotecan and cytarabine is an active combination regimen in myeiodysplastic syndromes and chronic myelomonocytic leukemia. J. Clin Oncol. ,1999, Vol.17, № 9, P.2819-2830.

Davis R. E., Greenberg P. L. Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: relation ti desease progression. Leuk Research, 1998, №22, P.767-777.

Deeg II., Beckham C., Loken M. et al. Negative regulators of hemopoiesis and stroma function in patients with myelodysplastic syndrome. Leuk. Lymphoma, 2000,Vol. 37, №3-4, P.405-414.

DiGiuseppe J. A., I.eBeau P., Augenbraun J., Borowitz M.J. Multiparameter flow-cytometric analysis of bcl-2 and Fas expression in normal and neoplastic hematopoiesis. Am. J. Clin. Pathol, 1996, Vol. 106, №3, P.345-351.

Duhrsen U., Hossfeld О. K. Stromal abnormalities in neoplastic bone marrow diseases. Ann. Hemat, 1996, №73,P.53-70.

Elihu H., Estey M. New agents for the treatment of acute myeloid leukemia. Leukemia, 1998, №12, P. 13-15.

Estey E., Thai! P., Andreeff M. et. Al. Use of granulocyte colony-stimulating factor before, during and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor.

Estey E., Thall P., Pierce S. et al. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyten colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndromes. Blood, 1999, Vol. 93, №8, P.2478- 2484.

Evan G. I., Wyillie A.M., Gilbert C.S., et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell, 1992, №62, P. 119-124.

Fanidi A., Harrington E.A., Evan G. 1. Interaction between c-myc and bcl-2 protooncogenes: A noval paradigm for oncogene cooperation. Nature, 1992, №359, P. 554-557.

Gupta P., Niehans G., LeRoy S. et al. Fas ligand expression in the bone marrow in myeiodysplastic syndromes correlates with FAB subtype and anemia, and predicts survival. Leukemia, 1999^felЗ, P. 44-53.

Hamada K., Takahashi I., Matsuoka M. et al. Apoptosis of peripheral leukocytes in patients with myeiodysplastic syndromes. Rinsho Kctsueki, 1998, Vol. 39, №11,P. 1079-1084.

Hanspal M., Smockova Y., Uong Q. Molecular identification and functional characterisation of a novel protein that mediates the attachment of erytroblaststomacrophages. Blood, 1998, Vol.92, P.2940-2950.

Hasle H., Jacobsen B.B. Brit. J. Haemat., 1992,-Vol. 81.-P. 495-498.

Hassan Z., Fadeel B., Zhivotovsky B. et al. Two pathways of apoptosis induced with all-trans retinoic acid and etoposide in the myeloid cell line P39. Exp. Hematol., 1999, Vol. 27,№3,P. 1322-1329.

Heim S. Cytogenetic findings in primary and secondary MDS. Leukemia Research, 1992, Vol. 16,№1,P. 43-46.

Heim S., Mitelman F. Cancer Cytogenetics Alan R. Liss. Inc. N. - Y. 1987. Heim S., Mitelman F. Cromosome abnormalities in the myeiodysplastic syndromes. Clin. Hematol. 1986. Vol. 15. P. 1003 - 1021.

Hellstrom - Linberg E., Ranter - Lewenson L, Ost A. Morphological changes and apoptosis in bone marrow from patients with myeiodysplastic syndromes treated with granulocyte-CSF and erythropoietin.

Ho S., Clipstone N., Timmermann L. et al. The mechanism of action of cyclosporin A and FK506. Clin. Immun. And lmmunopaph.,1996, Vol. 80, №3, P. 40-45.

Hofinan W., Ganser A., Seipeit G. et al. Treatment op patients with low- risk myeiodysplastic syndromes using a combination of all-trans retinoic acid, interferonalpha, and gpanulocyte colony-stimulating factor. Ann Hematol., 1999, Vol. 73, №3,P. 12-30.

51. Fenaux P., Morel P., Rose C. et al. Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. Br. J. Haemat. 1991,Vol. 77, P.497-501.

52. Fenaux P., Myelodysplastic syndromes. Textbook of malignant haematology -1999 -P. 787-813.

53. Ferrara F., Leoni F., Pinto A. et a!. Fludarabine, cytarabine and granulocyte colony-stimulating factor in the treatment of high risk myelodysplastic syndromes. Cancer, 1999, Vol 86, № 10, P. 2006-2013.

54. Florensa L, Vallespi T., Woessner S. et al. Incidence and characteristics of lymphoid malignance in untreatmed myelodysplastic syndrome. Leuk Lymphoma 1996, Vol. 23, №5-6, P. 609-612.

55. Gajate C., Santos-Beneit A., Macho A. et al. Involvement of mitochondria and caspase-3 in ET-18-OCH(3)-induced apoptosis of human leukemic cells. InL J. Cancer., 2000,Vol. 86, №2, P. 208-218.

56. Gerhartt H., Marcus R., Delmar A. et al. A randomized phase II study of low- dose cytosine arabinoside plus granulocyte-macrophage colony-stimulating factor (GM-CSF) in myelodysplastic syndromes with a high-risk of developing leukemia. Leukemia, 1994, №8,P. 16-23.

57. Germing U., Strupp C., Ktindgen A. et al. No evidence of incidence of MDS. Abstracts/Leukemia Res., 2003, Vol. 27, Suppl. 1, S2. .

58. Greenberg B. R., Wilson F .D., Wool. Granulopoietic effects of human bone marrow fibroblastic cells and abnormalities in the "granulopoietic microenvironment". Blood, 1981, Vol. 58, P. 557-564.

59. Greenberg P. L. Blood, 1983, Vol. 61, P. 1035 -1044.

60. Greenberg P., Cox C„ LeBeau M.M. et al. Blood, 1997, Vol. 89, P. 2079 - 2088.

61. Grub S., Persohn E., Trommer W. et al. Mechanism of cyclosporin A- induced apoptosis in rat hepatocyte primary cultures. Toxicol. Appl. Pharmacol., 2000,Vol. 163,№3, P .209-220.

73. Hofman W., Kalina U., Scipeit G. et al. Megakaryocytic growth in patients with refractory anemia is suppressed by treatment with interferon alpha. Bur. J. Haematol., 1999,Vol. 62, №5, P. 336-340.

74. Horigome A., Hirano T., Oka K. et al. Glucocorticoids and cyclosporine

induce apoptosis in mitogen-activated human peripheral mononuclear cells, lmmunopharmac., 1997,Vol. 37, P. 87-94.

75. Hortelano S., Lopez - Collazo E., Bosca L. Protective effect of cyclosporin A and FK506 from nitric oxide-dependent apoptosis in activated macrophages. Br. J. Pharmac. 1999,Vol. 126, №5, P.l 139-1146.

76. Intervizzi R., Pecci A., Rossi G. et al. Idarubicine and cytosine arabinoside in the induction and maintenance therapy of liigh-risk myelodysplastic syndromes. Hematologica, 1997, Vol. 82, P. 660-663.

77. Jackowska T., Rokicka - Milewska R., Pacholska J. et al. Myelodysplastic childhood syndromes: report of two cases started as refractory anemia. Clinical and Laboratory Studies 7-th International Symposium on Myelodysplastic Syndromes, 2003, abstr. P. 5.

78. Janasova A., Neuwirtova R., Cermak J. et al. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anemias without hypoplastic bone marrow. Br. J. Haematol., 1998,Vol. 100, P. 304-309.

79. Johnstone R., Cretney E., Smyth M. P-glycoprotein protects leukemia cells agains caspase-dependent, but not caspase-independent, cell death. Blood, 1999,Vol. 93, №3, P. 1075-1085.

80. Jonson E., Cotter F.E. Monosomy 7 and 7q- -associated with myeloid malignancy. Blood Rev., 1997, Jte 11, P. 46-55.

81. Jonveaux Ph. Mutation in the p53 gene in myelodysplastic syndromes. Oncogene 1991, №2, P. 2243-2248.

82. Kanavaros P., Stefanaki K., Rontogianni D. et al. Immunohistochemical detection of p53, mdm2, wafl/p2l and Ki-67 proteins in bone marrow biopsies in myelodysplastic syndromes, acute myelogenous leukemias and

Klimecki W., Heaton R., Glinsmann - Gibson B. et al. Amifostinc suppresses apoptosis in myelodysplastic CD34+ cells and promotes progenitor grownvia polyamine-like effects. Blood, 1997, Vol. 80, Suppl. 1, abstr. 520a.

Klimkovich N. Participation red cell membranes in development MDS at children. Clinical and Laboratory Studies 7-th International Symposium on Myelodysplastic Syndromes, 2003, abstr. P. 5 - 6.

Klimkovich N., Kozarezova T. The Histologic characteristic of a bone marrow at children with MDS. Clinical and Laboratory Studies 7-th International Symposium on Myelodysplastic Syndromes, 2003, abstr. P. 6.

Kozarezova T., Klimkovich N. Some epidemiological aspects MDS at children of Belarus. Clinical and Laboratory Studies 7-th Internationa] Symposium on Myelodysplastic Syndromes, 2003, abstr. P. 6.

Koike M., Ishiyama T., Tomoyasu et al. Spontaneous cytokine overproduction by peripheral blood mononuclear cells from patients with myelodysplastic syndromes and aplastic anemia. Leuk. Research, 1995, Vol. 19, № 9, P. 639-644.

Kuriya S., Murai K., Miyairi Y. et al. A combination chemotherapy with low- dose of cytarabine and etoposide of high-risk myelodysplastic syndromes and their leukemic stage. Cancer, 1996, Vol. 78, №3, P. 422-426.

Kurotaki H., Tsushima Y., Nagai K. ct al. Apoptosis, bcl-a expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic syndrome- derived acute myelogenous leukemia and de novo acute myelogenous leukemia. Acta Haematol., 2000, Vol. 102, №3, P. 115-123.

Kyriakou D., Eliopoulos A., Alexandrakis M. et al. Increase expression of c- myc p67 oncoprotein in patients with myelodysplastic syndromes in transformation to acute leukaemia. Haematologia, 1996, Vol. 28, №1, P. 1-7. Labat - Moleur F., Guillermet Ch., Lorimier Ph. et al. TUNEL apoptotic cell detection in tissue sections: critical evalution and improvement. The Jour. Of Histochemistry and cytochemistry, 1998, Vol. 46, №3, P. 327-334.

chronic myeloproliferative disorders. Clin. Exp. Pathol., 1999, Vol. 47, №5, P. 231-238.

Kaneko H., Misawa S., Horiike S. TP53 mutations emerge at early phase of myelodysplastic syndrome and are associated with complex chromosomal abnormalities. Blood, 1995, Vol. 85, №8, P. 2189-2193.

Kantrow S., Gierman J., Jaligram V. et al. Regulation of tumor necrosis factor cytotoxicity by calcineurin. FEBS Lett, 2000,Vol.483, №2-3, P.l 19-124. Kaplan E.L., Meier P. Non-parametric estimation from incomplete observations. J. Am. StaL Assoc. 1958,Vol. 53, №2-3, P.457 - 481.

Kerr J.F.R., Wyllie A.H., Currie A.R. Apoptosis: a basic biological phenomen with wide ranging implications in tissue kinetics. Brit. J. Cancer, 1972, Vol. 26, P. 239-257.

Kikukawa M., Aoki N., Sakamoto Y. et al. Study of p53 in elderly patients with myelodysplastic syndromes by immunohistochemistry and DNA analysis. Am. J. Pathol., 1999, Vol. 155, №3, P. 717-721.

Killick S., Marsh J., Gordon-Smith E. et al. In vitro antithymocyte globulin stimulation of hemopoietic stemm cells: correlation with clinical response in patients witn aplastic anemia and myelodysplastic syndromes. Blood, 1998, Vol. 92, №10, Suppl. 1, abst.2851.

Kitagawa M, Yoshida S., Kuwata T., Tanizawa T. p53 expression in myeloid cells of myelodysplastic syndromes. Association with evolution of overt leukemia. Am. J. Pathol., 1994, Vol. 145, №2, P. 338-344.

Kitagawa M., Saitol., Kuwata T. et al. Overexpression of tumor necrotic factor alpha and interferon-gamma by bone marrow cells from patients with myelodysplastic syndromes. Leukemia, 1997, №12, P. 2049-2054.

Kitagawa M., Yamaguchi S., Takahashi M. et al. Localization of Fas and Fas ligand in bone marrow cells demonstrating myelodysplasia. Leukemia, 1998, №12, P.486-492.

101.Lai J. Myelodysplastic syndrome and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoiesis and a high incidence P53 mutations. Leukemia, 1995, №9, P. 370-375.

102.Lcpclly P., Soenen V., Preudhomme C. et al. Expression of die multidrug resistance P-glycoprotein and its relationship to haematological characteristics and response to treatment in myelodysplastic syndromes. Leukemia, 1994, №6, P. 998-1004.

103.Lepelley P., Soenen V., Preudhomme C. ct al. Bcl-2 expression, in myelodysplastic syndromes and its correlation with haematological features, p53 mutations and prognosis. Leukemia, 1995, №9, P. 726-730.

104.Lepelley P., Campergue L., Grardel N. et al. Is apoptosis a massive procession myelodysplastic syndromes? Br. J. Haemat 1996,Vol. 95, P. 368- 371.

105.Lepelley P., Grardel N., Emy O. et al. Fas/Apo-1 (CD95) expression in myelodysplastic syndromes. Leuk. Lymphoma, 1998, Vol. 30, №3-4, P. 307-312.

106.List A. F., Brasfield F., Heaton R. et al. Stimulation of haematopoiesis by amifostine in patients with myelodysplastic syndrome. Blood, 1997, Vol. 90, P. 3364-3369.

107.List A. F. Pharmacological differentiation and anti-apoptotic therapy in myelodysplastic syndromes. Forum trends in experimental and clinic medicine, 1999, №9, P. 35-45.

108.Loosdrechl A. A., Vellcnga E. Myelodysplasia and apoptosis: new insighta into ineffective erytropoiesis. Medical Oncology, 2000, №17, P. 16-21.

109.Maciejewski J., Hibbs J., Anderson S. et al. Bone marrow and peripheral blood lymphocyte phenotype in patients with bone marrow failure. Exp. Hematol. 1994; 22; 1102-1110.

110.Maciejewski J., Selleri C., Anderson S. et al. Fas antigen expression on CD 34+ human marrow' cells induced by interferon у and tumor necrotic factor a and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood, 1995,Vol. 85, P. 3183-3189.

Molldrem J., Caples M., Mavroudis D. et al. Antithymocyte globulin for patients witn myelodysplastic syndromes. Br. J. Haematol. 1997,Vol. 99, P. 699- 705.

Molldrem J., Jiang Y., Mavroudis D. et al. Haematological response of patients witn myelodysplastic syndromes to antithymocyte globulin treatment is associated with a loss of CD8+ T-cell CFU-GM inhibition. Blood,

1997, Vol. 90, №10, abst. 369.

Mongkonsritragoon W., Lctendre L., Li C.Y. Multiple lymphoid nodules in marrow have the same clonality as underlying myelodysplastic syndrome recognised with fluorescent in situ hybridisation technique. Am. J. Hematol.

1998, Vol. 59, №3, P. 252-257.

Motomura S., Motoji T., Ocutomi К et al. Successful treatment of refractory anemia by high - dose methylprednisolone associated with an increment in CD68 - positive cells in bone marrow. Am. J. Hematol. 2001; 66; P. 80 - 84. Mufti G.J. Chromosomal deletions in the myelodysplastic syndrome. Leukemia Research, 1992, Vol. 16, №1, P. 35-41.

Mundle S., Venugopal P., Cartlidge J. et al. Indication of an involvement of interleukin-113 converting enzyme-like protease in intramedullary apoptotic cell death in the bone marrow' of patients with myelodysplastic syndromes. Blood, 1996, Vol. 88, №28, P. 2640-2647.

Mundle S., Ali A., Cartlidge J. et al. Evidence for involvement of tumor necrotic factor-alpha in apoptotic death of marrow cells in myelodysplastic syndromes. Am. J. Hematol., 1999, Vol. 60, №1, P. 36-47.

Mundle S., Mativi B., Bagai K. et al. Spontaneous dowm-regulation of Fas- associated phosphatase-1 may contribute to excessive apoptosis in myelodysplastic syndrome. Int. J. Haemat., 1999, Vol. 70, №2, P. 83-90. Mundle S., Venugopal P., Shetty V. The relative extent and propensity of CD34+VS. CD34- cells to undergo apoptosis in myelodysplastic marrows, hit. J. Haemat, 1999, Vol. 69, №3, P. 152-159.

111.Mangi M.N., Salisbury J. R., Patel N., et al. Bone marrow histological and immunohistological patterns in primary myelodysplastic syndromes. Br. J. Haemat 1990, Vol. 74, Suppr.l, P. 22-28.

112.Mangi M., Salisbury J., Mufti G. Abnormal localisation of immamure precursors (ALIP) in the bone marrow of myelodysplastic syndromes: current state of knowledge and future direction. Leuk. Research, 1991, Vol. 15, № 7, P. 627-639.

113.Mangi M.H., Mufti G.J. Primary myelodysplastic syndromes: diagnostic and prognostic significance of immunohistochemical assessment of bone marrow biopsies. Blood, 1992, Vol. 79, №1, P. 198-205.

114.Marsh J. C. W., Geary C. G. Br. J. Haemat. 1991, Vol. 77, P. 117 -122.

115.Maschek H., Kaloutsi V., Rodriguez-Kaiser M. et al. Ann. Hematol. 1993, Vol. 66, P. 117-122.

116.Maung Z.T., Maclean F. R., Reid M.M. et al. The relationship between bcl-2 expression and response to chemotherapy in acute leukemia. Br. J. Haemat., 1994, Vol. 88, P. 105-110.

117.McDonald J., Goldberg M., Gwag B. et al. Cyclosporine induces neuronal apoptosis and selective oligodendrocyte death in cortical cultures. Ann. Neurol., 1996,Vol. 40, №5, P. 750-758.

118.Mellibovsky L, Diez A., Perez-Vila E. et al. Vitamin D treatment in myelodysplastic syndromes. Br. J. Haematol. 1998,Vol. 100, №3, P. 516-520.

119.Michels S., Chan W., Jakubowsky D., Vogler R. Unclassifiable myelodysplastic syndrome: a stude of sixteen cases with proposals for a newsubtype. Lab. Invest. 1990, Vol. 62, P. 67 (abstr.).

120.Mineishi S., Filippa D., Childs B., et al. Blood, 1994, Vol. 84, №10. Suppl. 1. № 1245.

121.Misawa S., Horiike S. TP 53 mutations in myelodysplastic syndrome. Leuk. Lymphoma, 1996, Vol. 23, P. 417-422.

131.Nagata S., Golstein P. The Pas death factor. Science, 1995, Vol. 267, P. 1449-1455.

132.Nancy Lee Harris, Elaine S. Jaffe, Jacques Diebold et al. World Health Organization Classification of Neoplastic Diseases of die Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meetong- Airlie House, Virginia, November 1997. J. of Clin. Oncology, 1999, Vol.17, №12, P.3835-3849.

133.Ncmunaitis J., Rosenfeld C., Getty L. et al. Pentoxifylline and ciprofloxacin in patients with myelodysplastic syndromes. A phase II trial. Am. J. Clin. Oncol. 1995,Vol. 18,№3,P. 189-193.

134.Nisse C., Lorthois C., Dorp V. et al. Exposure to occupational and environmental factors in myelodysplastic syndromes. Preliminary results of a case-control study. Leukemia, 1995, № 9, P. 693-699.

135.Ohmori M., Ohmori S., Ueda Y. et al. Myelodysplastic syndrome (MDS) associated inhibitory activity on haemopoietic progenitor cells. Br. J. Haemat. 1990,Vol. 74, P. 179-184.

136.Ohyashiki K., Ohyashiki J.H., Iwabuchi A. ct al. Clinical aspects, cytogenetics and disease evolution in myelodysplastic syndromes. Leukemia and Lymphoma, 1996, Vol. 23, P. 409-415.

137.Ogata K., Yamata T., Ito T et al. Low-dosc ctoposide: a potential therapy for myelodysplastic syndromes. Br. J. Haemat., 1992, Vol. 827, P. 354-357.

138.Omoto D., Deguchi S., Takaba S. et al. Low-dose melphalana for treatment of high-risk myelodysplastic syndromes. Leukemia, 1996, №10, P. 609-614.

139.Oscier D.G. Myelodysplastic syndromes. In Haematological Problems inthe Eiderly. Balliere's Clinical Haematology, 1987, Vol. 1, №2, P. 389-426.

140.Pallis M., Russel N. P-glycoprotein plays a drug-efflux-independent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modulation of a sphingomyelin-ceramide apoptotic pathway. Blood, 2000,Vol. 95, №9, P. 2897-28904.

150.Raza A., Mundle S., Shetty V. et al. Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines. Int. J. Hematol. 1996, Vol. 63, №4, P. 265-278.

151.Raza A., Gezcr S., Venugopal P. et al. Hematopoietic and cytogenetic responses to novel anti-cytokine therapy in myelodysplastic syndromes. Proc ASCO, 1997, Vol. 16, abstr. 7a.

152.Raza A., Yousuf N., Abbas A. et al. High expression of transforming growth factor-beta long cell cycle times and a unique clustering of S-phase cells in patients with acute promyelocytic leukemia. Blood, 1992, Vol. 79, № 4, P. 1037- 1048.

153.Raza A., Qawi H., Lisak L. et al. Patients with myelodysplastic syndromes benefit from palliative therapy with amifostin, pentoxifylline and ciprofloxacin with or without dexamethasone. Blood, 2000, Vol. 95,№5, P. 1580-1587.

154.Remacha A. F., Arrizabalaga B., Villegas A. et al. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. Haematologica, 1999, Vol. 84, P. 1058-1064.

155.Rios A., Canizo M.C., Sanz M. A. et al. Bone marrow biopsy in myelodysplastic syndromes: morfological characteristics and contribution to the study of prognostic factors. Br. J. Haematol. 1990, Vol. 75, № 1, P. 26-33.

156.Rosenfeld C., List A. A hypothesis for the pathogenesis of myelodysplastic syndromes: implications for new therapies. Leukemia, 2000, №14, P. 2-8.

157.Ruuti T., Hanninen A., Jarvetie G. et al. Intensive chemotherapy of poor prognosis myelodysplastic syndromes (MDS) and acute myeloid leukemia following MDS with idarubicin and cytarabine. Leuk. Res., 1997, Vol. 21, №2, P. 133-138.

158.Santini V., Giles F.J. The potential of amifostine: from cytoprotectant to therapeutic agent. Haematologica, 1999, Vol. 84, №11, P. 1035-1042.

141.Parcharidov A., Raza A., Economopoulos T. et al. Extensive apoptosis of bone marrow cells as evaluated by the in situ end-labelling (ISEL) technique may be the basis for ineffective haematopoiesis in patients with myelodysplastic syndromes. Eur. J. Haemat, 1999, Vol. 62, №1, P. 19-26.

142.Parker J., Fishlock K., Mijovic A. et al. Low-risk myelodysplastic syndrome is associated with excessive apoptosis and an increase ratio of pro- versus anti-apoptotic bcl-2-related proteins. Br. J. Haemal, 1998, Vol. 103, №4, P. 1075-1082.

143.Perry S., Kim M., Spangrudc G. Direct effects of cyclosporine A on proliferation of hematopoietic stem and progenitor cells. Cell Transplant., 1999,Vol. 8, №4, P. 339-344.

144.Pradhan A., Mijovic A., Mills K. et al. Genes differentially expressed in adult familial myelodysplastic syndromes (MDS). Clinical and Laboratory Studies 7-th International Symposium on Myelodysplastic Syndromes, 2003, abstr. P. 6.

145.Pruneri G., Bertolini F., Soligo D. et al. Angiogenesis in myelodysplastic syndromes. Br. J. Cancer, 1999,Vol. 81, № 8, P. 1398-1401.

146.Qawi H., Goyal R., Ali I. et al. Biologic characteristics of patients with hypoccllular myelodysplastic syndromes. Leuk. Research, 1999, №23, P. 357- 364.

147.Rajapaska R. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood, 1996, Vol. 88, №11, P. 4275- 4282.

148.Raza A., Gregory S., Mundle S. et al. Increased apoptosis as the significant cause of ineffective hematopoietic in myelodysplastic syndromes. Blood, 1994,Vol.84, №10, Suppl. 1, abst. 2528.

149.Raza A., Gezer S., Mundle S. et al Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cell 50 patients with myelodysplastic syndrome. Blood, 1995, Vol. 86, № 1, P. 486-492.

159.Sanz G.F., Sanz M. A. Prognostic factors in myelodysplastic syndromes. Leukemia Research, 1992, Vol. 16, №1, P. 77-86.

160.Sanz M. A., Sanz G.F., Vallespi T. A patient-orieted approach to treatment of myelodysplastic syndrome. Hematologica, 1998, Vol. 83, P. 910- 935.

161.Saunthararajah Y., Molldrem J., Rivera M. et al. Coincident myelodysplastic syndrome and T cell large granular lymphocytic disease: clinical and pathophysiological features. Br. J. Hematol. 2001; 112; P. 195 - 200.

162.Searle J., Kerr J.F.R., Bishop C. J. Necrosis and Apoptosis: distinct modes of cell death with fundamentally different significance. 1982, Pathol. Annual. Vol. 17, P. 229-259.

163.Shetty V., Mundle S., Alvi S. et al. Measurement of apoptosis, proliferation and tree cytokines in 46 patients with myelodysplastic syndromes. Leuk. Research, 1996, Vol. 20, № 11-12, P. 891-900.

164.Shibata K., Shimamoto Y., Nakazato S. et al. Refractory' anemia with ringer sideroblasts concurrent with multiple myeloma-a brief review of the recent literature. Haematologia 1997, Vol. 28, №4, P. 199-205.

165.Shihab F., Andoh T., Tanner A. et al. Expression of apoptosis regulatory genes in chronic cyclosporine nephrotoxicity favors apoptosis. Kidney Int, 1999, Vol.56, №6, P. 2147-2159.

166.Shimazaki K., Ohshima K., Suzumija J. et al. Evalution of apoptosis as a prognostic factor in myelodysplastic syndromes. Br. J. Haematol., 2000, Vol. 110, №3, P. 584-590.

167.Span L, Dar S., Shetty. et al. Apparent expansion of CD34+ cells during the evolution of myelodysplastic syndromes and acute myeloid leukemia. Leukemia, 1998,№11,P. 1685-1695.

168.Stasi R., Brunetti M., Bussa S. et al. Serum levels of tumor necrotic factor- alpha predicts response to recombinant human crytropoietin patients with myelodysplastic syndromes. Clin. Lab. Haematol., 1997, №19, P. 197-201.

syndromes and secondary leukemia. Preliminary results of a randomized trial. Blood, 1998, Vol. 86, Suppl.l, abst. 804a.

Wetzler M., Kurzrock R., Estrov Z. et al. Cytokine expression in adherent layers patients with myelodysplastic syndromes and acute myelogenous leukemia. Leuk. Research, 1995, Vol. 19, P. 23-34.

Wickremasinglc R., Hoffbrand A. Biochemical and genetic control of apoptosis: relevance to normal hemapoeisis and haematological malignancies. Blood, 1999, Vol. 93, №11, P. 3587-3600.

De Witte T., Van Biezen A., Hermans J. et al. Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS. Blood, 1997, Vol.90, P. 3853-3859.

Yang E., Korsmeier S.J. Molecular thanatopsis: a discourse on the bcl-2 family and cell death. Blood, 1996, Vol. 88, №26, P. 386-401.

Yi F., Wang B., Liu X. The significance of Ki-67, BrdU and OKT9 expression in determination of myelodysplastic syndromes by use of APAAP technique. J. Tongji Med. Univ.1993, Vol.13, №1, P.30-33.

Yoshida Y. Hypothesis: apoptosis may be the mechanism responsible for the premature intramedullaiy cell death in the myelodysplastic syndrome. Leukemia, 1993, №7, P. 144-146.

Zipori D., Reichman N., Arcari L. et al. In vitro functions of stromal cells from human and mouse bone marrow. Exp. Hematol. 1985, №13, P. 603-609. Zouchauer S., Gsur A., Gotzl M. et al. MDR1 gene expression in myelodysplastic syndrome and in acute myeloid leukemia evolving from myelodysplastic syndrome. Anticancer Res, 1994,Vol 14, №3B, P.1293-1295.

169.Stoetzer O.J., Nussler V., Darsow. M. et al. Association of bcl-2, bax, bcl-xl and interleukin -ip-converting enzyme expression with initial response to chemotherapy in acute myeloid leukemia. Leukemia, 1996, №10. P. 18-22.

170.Sugano N., Ito K., Murai S. Cyclosporin A inhibits H2O2-induced apoptosis of human fibroblasts. FEBS Lett, 1999,Vol. 447, №2-3, P. 274-276.

171.Tang J., Tien H., Lin M. et al. p53 mutation in advanced stage of primary myelodysplastic syndromes. Anticancer, 1998, Vol. 18, №5B, P. 3757- 3761.

172.Thompson J., Gilliand D., Prchal J. et al. Effect of recombinant human erythropoietic combined with granulocyte macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndromes. Blood, 2000, Vol. 95, №4, P. 1175-1179.

173.Trigot G., De Wolf-Peeters C., Hendrickx B. Histological findings in myelodysplastic syndromes and comparison with bone marrow smears. Br. J. Haematol., 1984, № 57, P. 423-427.

174.Trigot G. J. Prognostic factors in the myelodysplastic syndromes. Leukemia Research, 1992, Vol. 16,№1,P. 109-115.

175.Tuncer M.A., Pagliuca A., Hicsonmez G. et al. Brit. J. Haemat.-1992.-Vol. 82.-P. 347-353.

176.Van den Berghe J., Vcrmaelen K., Meccuci C. et al. 5q anomaly. Cancer Genet Cytogenct. - 1985. Vol - 17. P. 189 - 255.

177.Verhoef G., De Schouwer P., Ceuppens J. et al. Measurement of serum cytokine levels in patients with myelodysplastic syndromes. Leukemia, 1992, №12, P. 1268-1272.

178.Waring P., Beaver J. Cyclosporine A rescues thymocytes from apoptosis induced bu very low concentrations of thapsigargin: effects on mitochondrial function. Exp. Cell Res., 1996, Vol. 227, №2, P. 264-276.

179.Wattel E., Solary E., Caillot D. et al. Intensive chemotherapy with or without quinine followed by autologous BMT in myelodysplastic